Drugs / pBI-11
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06210854 | Jun 2026 → Nov 2028 expected | human papilloma virus infection | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 2 | NCT05799144 | Jul 2023 → Sep 2027 expected | oropharyngeal carcinoma | Michael K. Gibson | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pBI-11 | “pBI-11 is a circular deoxyribonucleic acid (DNA) (plasmid) vaccine” NCT05799144 ↗ |
| Known as | pBI-11 plasmid DNA | “pBI-11 plasmid DNA” NCT06210854 ↗ |
| Modality | Vaccine | “pBI-11 is a circular deoxyribonucleic acid (DNA) (plasmid) vaccine” NCT05799144 ↗ |
| Route | Intramuscular | “Patients receive pBI-11 vaccine intramuscularly (IM), TA-HPV vaccine IM, and pembrolizumab intravenously (IV) on study.” NCT05799144 ↗ |